	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S4-PMC2682672	PMC2682672	6/2009	S4-PMC2682672	['research design and methods\nwe genotyped single-nucleotide polymorphisms (snps) at five recently identified type 2 diabetes loci ( cdkal1 , cdkn2a/b , hhex-ide , igf2bp2 , and slc30a8 ) in 7,986 mothers and 19,200 offspring from four studies of white europeans.']	[('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 97)]	2	[('SO_0000694', 'SNP', 41, 'single-nucleotide polymorphisms'), ('SO_0000694', 'SNP', 74, 'SNPs'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 131, 'CDKAL1'), ('PR_000005209', 'Cdc42 effector protein 2', 140, 'CDKN2A'), ('PR_000008940', 'intraflagellar transport protein 88', 162, 'IGF2BP2'), ('PR_000015122', 'sodium-coupled neutral amino acid transporter 5', 176, 'SLC30A8')]
S6-PMC2682672	PMC2682672	6/2009	S6-PMC2682672	['results\nwe found that type 2 diabetes risk alleles at the cdkal1 and hhex-ide loci were associated with reduced birth weight when inherited by the fetus (21 g [95% ci 11–31], p = 2 × 10−5, and 14 g [4–23], p = 0.004, lower birth weight per risk allele, respectively).']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('SO_0001023', 'allele', 43, 'alleles'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 58, 'CDKAL1'), ('GO_0007567', 'parturition', 112, 'birth'), ('GO_0007567', 'parturition', 223, 'birth'), ('SO_0001023', 'allele', 245, 'allele')]
S26-PMC2682672	PMC2682672	6/2009	S26-PMC2682672	['we selected variants at five loci ( cdkal1 , cdkn2a/b , hhex-ide , igf2bp2 , and slc30a8 ), recently identified through type 2 diabetes genome-wide association studies (16–21), that have not been investigated in relation to fetal growth.']	[('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 101), ('FULL_UNKNOWN', 182), ('SUPERFICIAL_RELATIONSHIP', 212)]	4	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 36, 'CDKAL1'), ('PR_000005209', 'Cdc42 effector protein 2', 45, 'CDKN2A'), ('PR_000008940', 'intraflagellar transport protein 88', 67, 'IGF2BP2'), ('PR_000015122', 'sodium-coupled neutral amino acid transporter 5', 81, 'SLC30A8'), ('SO_0001026', 'genome', 136, 'genome')]
S43-PMC2682672	PMC2682672	6/2009	S43-PMC2682672	['one single nucleotide polymorphism (snp) was chosen to represent the type 2 diabetes association signal at each of the five loci (rs10946398 [ cdkal1], rs10811661 [ cdkn2a/b], rs1111875 [ hhex-ide], rs4402960 [ igf2bp2], and rs13266634 [ slc30a8]).']	N/A	N/A	[('SO_0000694', 'SNP', 4, 'single nucleotide polymorphism'), ('SO_0000694', 'SNP', 36, 'SNP'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 143, 'CDKAL1'), ('PR_000005209', 'Cdc42 effector protein 2', 165, 'CDKN2A'), ('PR_000008940', 'intraflagellar transport protein 88', 211, 'IGF2BP2'), ('PR_000015122', 'sodium-coupled neutral amino acid transporter 5', 238, 'SLC30A8')]
S65-PMC2682672	PMC2682672	6/2009	S65-PMC2682672	['analysis of the combined effects of cdkal1 and hhex-ide on birth weight.']	[('SUPERFICIAL_RELATIONSHIP', 25)]	1	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 36, 'CDKAL1'), ('GO_0007567', 'parturition', 59, 'birth')]
S66-PMC2682672	PMC2682672	6/2009	S66-PMC2682672	['to assess the combined effect of the fetal risk alleles at cdkal1 and hhex-ide on birth weight, we generated a risk allele score (from 0 to 4) for individuals genotyped at both loci.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 23)]	2	[('SO_0001023', 'allele', 48, 'alleles'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 59, 'CDKAL1'), ('GO_0007567', 'parturition', 82, 'birth'), ('SO_0001023', 'allele', 116, 'allele'), ('NCBITaxon_1', 'root', 147, 'individuals')]
S70-PMC2682672	PMC2682672	6/2009	S70-PMC2682672	['results\nthe fetal risk alleles of snps rs10946398 ( cdkal1 ) and rs1111875 ( hhex-ide ) were associated with reduced birth weight in the meta-analysis (21 g [95% ci 11–31], p = 2 × 10−5, and 14 g [4–23], p = 0.004, lower birth weight per risk allele, respectively) (table 2andfig.']	[('SUPERFICIAL_RELATIONSHIP', 93)]	1	[('SO_0001023', 'allele', 23, 'alleles'), ('SO_0000694', 'SNP', 34, 'SNPs'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 52, 'CDKAL1'), ('GO_0007567', 'parturition', 117, 'birth'), ('GO_0007567', 'parturition', 221, 'birth'), ('SO_0001023', 'allele', 243, 'allele')]
S78-PMC2682672	PMC2682672	6/2009	S78-PMC2682672	['a : meta-analysis plot showing the association of fetal cdkal1 genotype with birth weight across all four studies (overall p = 2 × 10−5; total n = 18,679; heterogeneity statistics: i2= 19.9%, p = 0.29).']	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 56, 'CDKAL1'), ('GO_0007567', 'parturition', 77, 'birth')]
S81-PMC2682672	PMC2682672	6/2009	S81-PMC2682672	['caption (table-wrap): table 3\n\nanalysis of fetal genotype and birth weight within four studiesgenotype (number of type 2 diabetes risk alleles)total n per–risk allele effect size (g)* p *012 n mean birth weight (g) n mean birth weight (g) n mean birth weight (g)rs10946398 ( cdkal1 )\u2003\u2003\u2003\u2003alspac3,496 (3,481–3,510)3,4943,471 (3,456–3,486)3,2103,462 (3,431–3,494)7587,462−20 ± 80.010\u2003\u2003\u2003\u2003efsoch3,512 (3,466–3,557)3503,504 (3,457–3,551)3293,520 (3,420–3,620)72751−1 ± 240.983\u2003\u2003\u2003\u2003nfbc19663,568 (3,546–3,589)1,7953,516 (3,497–3,534)2,2953,506 (3,474–3,539)7424,832−35 ± 100.0002\u2003\u2003\u2003\u20031958bc3,380 (3,362–3,397)2,6753,367 (3,348–3,386)2,3543,354 (3,319–3,390)6055,634−13 ± 90.162rs10811661 ( cdkn2a/b )\u2003\u2003\u2003\u2003alspac3,451 (3,395–3,507)2363,482 (3,463–3,500)2,1053,483 (3,471–3,495)5,1767,5177 ± 90.465\u2003\u2003\u2003\u2003efsoch3,396 (3,196–3,597)183,506 (3,443–3,569)1823,509 (3,473–3,545)55475420 ± 310.515\u2003\u2003\u2003\u2003nfbc19663,543 (3,463–3,624)1253,523 (3,498–3,549)1,2493,537 (3,522–3,552)3,4484,8228 ± 130.539\u2003\u2003\u2003\u20031958bc3,349 (3,283–3,414)1623,358 (3,335–3,380)1,6183,380 (3,365–3,394)3,8785,65820 ± 110.084rs1111875 ( hhex/ide )\u2003\u2003\u2003\u2003alspac3,529 (3,505–3,553)1,2893,475 (3,461–3,489)3,6523,471 (3,454–3,488)2,5737,514−25 ± 70.0007\u2003\u2003\u2003\u2003efsoch3,495 (3,421–3,569)1323,509 (3,464–3,555)3503,505 (3,453–3,556)2757573 ± 220.894\u2003\u2003\u2003\u2003nfbc19663,547 (3,520–3,574)1,1003,536 (3,518–3,554)2,4663,516 (3,490–3,541)1,2664,832−16 ± 90.095\u2003\u2003\u2003\u20031958bc3,373 (3,345–3,400)1,0203,372 (3,355–3,389)2,8363,375 (3,355–3,395)1,9995,8551 ± 90.872rs4402960 ( igf2bp2 )\u2003\u2003\u2003\u2003alspac3,480 (3,466–3,494)3,7183,481 (3,466–3,497)3,1283,500 (3,468–3,533)6927,5387 ± 80.385\u2003\u2003\u2003\u2003efsoch3,469 (3,423–3,514)3453,554 (3,508–3,599)3463,443 (3,336–3,550)6375429 ± 250.247\u2003\u2003\u2003\u2003nfbc19663,536 (3,518–3,555)2,3863,528 (3,509–3,555)1,9723,540 (3,498–3,583)4464,804−2 ± 100.829\u2003\u2003\u2003\u20031958bc3,375 (3,356–3,393)2,4133,366 (3,348–3,385)2,1723,391 (3,351–3,430)5065,0912 ± 100.851rs13266634 ( slc30a8 )\u2003\u2003\u2003\u2003alspac3,471 (3,438–3,504)6663,480 (3,465–3,495)3,1783,485 (3,471–3,499)3,6197,4636 ± 80.422\u2003\u2003\u2003\u2003efsoch3,421 (3,315–3,528)633,548 (3,501–3,596)3153,479 (3,435–3,523)368746−13 ± 250.613\u2003\u2003\u2003\u2003nfbc19663,504 (3,469–3,540)6313,536 (3,517–3,555)2,2743,512 (3,521–3,562)1,9334,83815 ± 100.124\u2003\u2003\u2003\u20031958bc3,321 (3,284–3,358)5583,372 (3,353–3,390)2,3833,377 (3,359–3,394)2,7145,65519 ± 90.037\ndata are means (95% ci) or means ± se, unless otherwise indicated.']	N/A	N/A	[('GO_0007567', 'parturition', 62, 'birth'), ('SO_0001023', 'allele', 135, 'alleles'), ('SO_0001023', 'allele', 160, 'allele'), ('GO_0007567', 'parturition', 198, 'birth'), ('GO_0007567', 'parturition', 222, 'birth'), ('GO_0007567', 'parturition', 246, 'birth'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 275, 'CDKAL1'), ('PR_000003890', 'A-kinase anchor protein 3', 287, 'ALSPAC3'), ('PR_000005209', 'Cdc42 effector protein 2', 681, 'CDKN2A'), ('PR_000003890', 'A-kinase anchor protein 3', 695, 'ALSPAC3'), ('PR_000006940', 'early growth response protein 4', 790, 'EFSOCH3'), ('PR_000003890', 'A-kinase anchor protein 3', 1097, 'ALSPAC3'), ('PR_000008940', 'intraflagellar transport protein 88', 1493, 'IGF2BP2'), ('PR_000003890', 'A-kinase anchor protein 3', 1506, 'ALSPAC3'), ('PR_000015122', 'sodium-coupled neutral amino acid transporter 5', 1895, 'SLC30A8'), ('PR_000003890', 'A-kinase anchor protein 3', 1908, 'ALSPAC3'), ('PR_000006940', 'early growth response protein 4', 2003, 'EFSOCH3')]
S86-PMC2682672	PMC2682672	6/2009	S86-PMC2682672	['for cdkal1 , the per–risk allele effect size estimate of the association between fetal genotype and birth weight was −25 g (95% ci −43 to −7) ( p = 0.005) before adjustment for maternal genotype and −36 g (−56 to −16) ( p = 0.0005) after adjustment.']	N/A	N/A	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 4, 'CDKAL1'), ('SO_0001023', 'allele', 26, 'allele'), ('GO_0007567', 'parturition', 100, 'birth')]
S87-PMC2682672	PMC2682672	6/2009	S87-PMC2682672	['in accordance with this, the maternal risk allele at cdkal1 showed a nominal association with increased birth weight after adjustment for fetal genotype ( p = 0.04).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 60), ('SUPERFICIAL_RELATIONSHIP', 77)]	3	[('SO_0001023', 'allele', 43, 'allele'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 53, 'CDKAL1'), ('GO_0007567', 'parturition', 104, 'birth')]
S90-PMC2682672	PMC2682672	6/2009	S90-PMC2682672	['using 18,438 individuals from all four studies, we combined information from the cdkal1 and hhex-ide loci into a fetal risk allele score and tested the association with birth weight.']	[('SUPERFICIAL_RELATIONSHIP', 152)]	1	[('NCBITaxon_1', 'root', 13, 'individuals'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 81, 'CDKAL1'), ('SO_0001023', 'allele', 124, 'allele'), ('GO_0007567', 'parturition', 169, 'birth')]
S96-PMC2682672	PMC2682672	6/2009	S96-PMC2682672	['bar graph showing the association between birth weight and the number of fetal type 2 diabetes risk alleles at cdkal1 (rs10946398) and hhex-ide (rs1111875) across all four studies ( n = 18,438).']	[('SUPERFICIAL_RELATIONSHIP', 22)]	1	[('GO_0007567', 'parturition', 42, 'birth'), ('SO_0001023', 'allele', 100, 'alleles'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 111, 'CDKAL1')]
S99-PMC2682672	PMC2682672	6/2009	S99-PMC2682672	['discussion\nusing a total of 19,200 offspring and 7,986 mothers from four studies of white europeans, we have shown that fetal inheritance of the type 2 diabetes risk alleles at cdkal1 and hhex-ide is associated with reduced birth weight.']	[('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 200)]	2	[('SO_0001023', 'allele', 166, 'alleles'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 177, 'CDKAL1'), ('GO_0007567', 'parturition', 224, 'birth')]
S105-PMC2682672	PMC2682672	6/2009	S105-PMC2682672	['when we assessed the effects of maternal and fetal genotype that were independent of one another using mother-offspring pairs, the effect size of the association between fetal genotype and birth weight at cdkal1 changed from −25 g (95% ci −43 to −7) to −36 g (−56 to −16).']	[('SUPERFICIAL_RELATIONSHIP', 21), ('SUPERFICIAL_RELATIONSHIP', 150)]	2	[('GO_0007567', 'parturition', 189, 'birth'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 205, 'CDKAL1')]
S113-PMC2682672	PMC2682672	6/2009	S113-PMC2682672	['third, our statistical evidence for association of cdkal1 ( p = 2 × 10−5) and hhex-ide ( p = 0.004) with birth weight does not meet the generally accepted criterion for genome-wide adjustment.']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 36), ('PROBABLE_UNDERSTANDING', 136)]	3	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 51, 'CDKAL1'), ('GO_0007567', 'parturition', 105, 'birth'), ('SO_0001026', 'genome', 169, 'genome')]
S121-PMC2682672	PMC2682672	6/2009	S121-PMC2682672	['if a variant reduces fetal insulin secretion in utero, this could result in reduced birth weight (e.g., cdkal1 and hhex-ide ).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 60)]	2	[('PR_000045358', 'insulin family protein', 27, 'insulin'), ('GO_0007567', 'parturition', 84, 'birth'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 104, 'CDKAL1')]
S133-PMC2682672	PMC2682672	6/2009	S133-PMC2682672	['risk alleles at cdkal1 and hhex-ide are both associated with reduced birth weight.']	[('SUPERFICIAL_RELATIONSHIP', 45)]	1	[('SO_0001023', 'allele', 5, 'alleles'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 16, 'CDKAL1'), ('GO_0007567', 'parturition', 69, 'birth')]
S74-PMC3031146	PMC3031146	1/2011	S74-PMC3031146	['q-values were calculated using the qvalue package in the r statistical programming environment under default settings (seematerials and methods).10.1371/journal.pone.0016506.t004\n\ncaption (table-wrap): table 4\ndifferentially methylated mirnas.genemirnap-value1q-value2direction of methylation in caseschromosomecpg island hoxb4 hsa-mir-10a;0.00433840.1822456+17yes btg4 hsa-mir-34b;hsa-mir-34c;0.00066630.1708606+11yes ccdc55 hsa-mir-423;0.00295420.1822456-17yes sacm1l hsa-mir-565;0.00080430.1743975+3yes hspc268 hsa-mir-594;0.00004630.1708606+7yes hspc268 hsa-mir-594;0.00457670.1822456+7yes wdr37 hs_104;0.00333060.1822456+10yes dusp4 hs_128;0.00340430.1822456+8yes c10orf4 hs_138;0.00261440.1822456+10yes pigo hs_140;0.00445430.1822456+9yes ppme1 hs_176;0.00155820.1822456+11yes dus2l hs_253;hs_253;0.00413220.1822456-16yes cdc7 hs_255;0.00493220.1822456+1yes fbxo28 hs_78;0.00150550.1822456+1yes\np-values were calculated by multiple linear regression model and randomization testing (seematerials and methods).']	N/A	N/A	[('SO_0000276', 'miRNA', 236, 'miRNAs'), ('SO_0001026', 'genome', 243, 'GenemiRNAp'), ('PR_000008689', 'homeobox protein Hox-A13', 322, 'HOXB4'), ('PR_000006745', 'dual specificity protein phosphatase 19', 632, 'DUSP4'), ('PR_000030490', 'mucin-22', 669, 'C10orf4'), ('PR_000013100', 'protein phosphatase 1M', 745, 'PPME1'), ('PR_000006743', 'dual specificity protein phosphatase 16', 783, 'DUS2L'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 828, 'CDC7')]
S60-PMC3208550	PMC3208550	11/2011	S60-PMC3208550	['the sequences of the primers are intable 1.10.1371/journal.pone.0025726.t001\n\ncaption (table-wrap): table 1\nprimer sequences used for mrna quantification by real-time pcr.forward primer 5′–3′reverse primer 5′–3′11β-hsd1 gaa gaa gca tgg agg tca ac  gca atc aga ggt tgg gtc at 5αr1 ctg ttt cct gac agg ctt tgc  gcc tcc cct ggg tat ctt gt 5βr gcc ttt aag cct gga gag gaa  acg tgg cac aca gat ttg att gr ggg tac tca agc cct gga atg  ccc gta atg aca tcc tga agc t c/ebpα ggc ggg aac gca aca a  tcc acg ttg cgc tgt ttg c/ebpβ tct act acg agc ccg act gc  agg tag ggg ctg aag tcg at gapdh caa gtt caa cgg cac agt caa  tgg tga aga cgc cag tag act c \n11β-hsd1, 11β-hydroxysteroid dehydrogenase type 1; 5αr1, 5α-reductase type 1; 5βr, 5β-reductase; gr, glucocorticoid receptor; c/ebpα, ccaat/enhancer-binding protein α; c/ebpβ, ccaat/enhancer-binding protein β; gapdh, glyceraldehyde-3-phosphate dehydrogenase.']	N/A	N/A	[('SO_0000112', 'primer', 21, 'primers'), ('SO_0000112', 'primer', 108, 'Primer'), ('SO_0000121', 'forward_primer', 171, 'Forward primer'), ('SO_0000132', 'reverse_primer', 191, 'Reverse primer'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 211, '11β-'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 215, 'HSD1'), ('PR_000001623', 'neuropeptide Y receptor type 4', 275, '5αR1'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 461, 'EBPα'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 515, 'EBPβ'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 641, '11β-HSD1'), ('CHEBI_36858', '2alpha-hydroxy steroid', 651, '11β-hydroxysteroid'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 651, '11β-hydroxysteroid dehydrogenase type 1'), ('PR_000001623', 'neuropeptide Y receptor type 4', 692, '5αR1'), ('CHEBI_24261', 'glucocorticoid', 742, 'glucocorticoid'), ('PR_000003199', 'calcium/calmodulin-dependent protein kinase type II subunit alpha', 767, 'C/EBPα'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 775, 'CCAAT/enhancer-binding protein α'), ('SO_0000165', 'enhancer', 781, 'enhancer'), ('PR_000004967', 'calbindin', 809, 'C/EBPβ'), ('PR_000007208', 'steroid hormone receptor ERR1', 823, 'enhancer-binding protein β'), ('SO_0000165', 'enhancer', 823, 'enhancer'), ('CHEBI_17270', 'glycerol 2-phosphate', 858, 'glyceraldehyde-3-phosphate')]
S158-PMC3335729	PMC3335729	3/2012	S158-PMC3335729	['dolinoy and colleagues found that prenatal exposure to bpa through maternal dietary supplementation (50\u2009mg/kg) produced significantly decreased methylation of nine sites of the avylocus, as well as at the cdk5 activator-binding protein locus [127].']	[('INCOMPLETE_EVIDENCE', 23)]	1	[('GO_0007565', 'female pregnancy', 34, 'prenatal'), ('CHEBI_34018', '(S)-AMPA', 55, 'BPA'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 205, 'CDK5')]
S214-PMC3674738	PMC3674738	5/2013	S214-PMC3674738	['cystathionine beta-synthetase (cbs) deficiency is the most common of the homocysteinemias, with severe defects involving multiple systems due to the essentiality of homocysteine and methionine to normal biochemical function.']	[('IMPORTANT_CONSIDERATION', 96)]	1	[('CHEBI_17755', 'cystathionine', 0, 'Cystathionine'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 31, 'CBS')]
S51-PMC3774699	PMC3774699	10/2013	S51-PMC3774699	['caloric restriction increased ccaat/enhancer-binding protein α (cebpα) expression in all animals, though only al males showed a significant increase (fig.']	[('ANOMALY_CURIOUS_FINDING', 98), ('ANOMALY_CURIOUS_FINDING', 105)]	2	[('CHEBI_81905', '3A-Deolivosylpremithramycin B', 0, 'Caloric'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 30, 'CCAAT/enhancer-binding protein α'), ('SO_0000165', 'enhancer', 36, 'enhancer'), ('PR_000005311', 'CCAAT/enhancer-binding protein gamma', 64, 'CEBPα'), ('GO_0010467', 'gene expression', 71, 'expression'), ('NCBITaxon_33208', 'Metazoa', 89, 'animals')]
S106-PMC3828638	PMC3828638	11/2013	S106-PMC3828638	['over the past two decades, studies using siberian hamsters have thoroughly and systematically determined how appetitive ingestive behaviors are affected by fasting, diet dilution and lipectomy as well as treatment with orexigenic factors such as npy, y1r agonists, agrp, and ghrelin and anorexigenic factors such as leptin, mt-ii, cck, and y1r antagonists (bartness and clein,1994; bartness et al.,2011; wood and bartness,1996a,b; bartness,1997; day and bartness,2003,2004; day et al.,2005; keen-rhinehart and bartness,2005,2007; keen-rhinehart et al.,2010; teubner and bartness,2010; teubner et al.,2012).']	[('INCOMPLETE_EVIDENCE', 27), ('EXPLICIT_QUESTION', 105), ('SUPERFICIAL_RELATIONSHIP', 144)]	3	[('GO_0000239', 'pachytene', 109, 'appetitive'), ('GO_0006885', 'regulation of pH', 120, 'ingestive behaviors'), ('GO_0042476', 'odontogenesis', 219, 'orexigenic'), ('CHEBI_7440', 'NOP', 246, 'NPY'), ('PR_000011368', 'N-acetylneuraminate lyase', 246, 'NPY'), ('PR_000017515', 'xylosyltransferase 1', 251, 'Y1R'), ('CHEBI_33252', 'atomic nucleus', 255, 'agonists'), ('PR_000003580', 'ABI gene family member 3', 265, 'AgRP'), ('PR_000007988', 'gastric inhibitory polypeptide receptor', 275, 'ghrelin'), ('PR_000010699', 'metallothionein-1G', 324, 'MT-II'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 331, 'CCK'), ('PR_000017515', 'xylosyltransferase 1', 340, 'Y1R')]
S33-PMC3953741	PMC3953741	3/2014	S33-PMC3953741	['in several models of oxidative stress, it has been demonstrated that a cell may selectively shunt metabolites from the methionine cycle (figure 2), down the transsulfuration pathway at the expense of s-adenosylmethionine in order to increase the synthesis of glutathione (gsh), a scavenger of ros, in an effort to combat oxidative stress.20,21independently, bravo et al22showed that in rats fed a hf diet, expression of the enzymes cystathionine β-synthase (cbs) and cystathionine γ-lyase, which participate in the transsulfuration pathway, were significantly downregulated.22cbs is a necessary enzyme that is involved in the redirection of homocysteine from the methionine cycle toward gsh synthesis, which occurs in the first step of the transsulfuration pathway.21in conjunction with pressure to generate gsh to neutralize ros, homocysteine levels are elevated (figure 2).']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 610)]	4	[('CHEBI_25212', 'metabolite', 98, 'metabolites'), ('GO_0007049', 'cell cycle', 130, 'cycle'), ('CHEBI_50758', 'N-hydroxydihomomethionine', 200, 's-adenosylmethionine'), ('GO_0006750', 'glutathione biosynthetic process', 246, 'synthesis of glutathione'), ('CHEBI_16856', 'glutathione', 259, 'glutathione'), ('CHEBI_16856', 'glutathione', 272, 'GSH'), ('GO_0001837', 'epithelial to mesenchymal transition', 272, 'GSH'), ('CHEBI_8756', 'RNA (poly(A))', 293, 'ROS'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 386, 'rats'), ('GO_0007631', 'feeding behavior', 391, 'fed'), ('GO_0010467', 'gene expression', 406, 'expression'), ('PR_000006022', 'lysosomal protective protein', 432, 'cystathionine β-synthase'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 458, 'CBS'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 641, 'homocysteine'), ('GO_0007049', 'cell cycle', 674, 'cycle'), ('CHEBI_16856', 'glutathione', 687, 'GSH'), ('GO_0042082', 'GSI anchor biosynthetic process', 687, 'GSH synthesis'), ('CHEBI_16856', 'glutathione', 808, 'GSH'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 831, 'homocysteine')]
S36-PMC3953741	PMC3953741	3/2014	S36-PMC3953741	['it is possible that mild hyperhomocysteinemia, due to the downregulation of cbs and the diversion of methionine cycle metabolites down the transsulfuration pathway, is responsible for the downregulation of antioxidant enzymes, as noted by zhang et al.25in the study by byrne18discussed earlier, the mice fed a c diet in utero and a hf diet postnatally (c/hf) did not display altered etc complex i activity, and it is possible that this is because their levels of ros-neutralizing antioxidant enzymes were not downregulated during development and, consequently, mtdna damage did not occur.']	[('INCOMPLETE_EVIDENCE', 0), ('DIFFICULT_TASK', 387), ('INCOMPLETE_EVIDENCE', 411), ('PROBABLE_UNDERSTANDING', 439), ('PROBABLE_UNDERSTANDING', 547)]	5	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 76, 'CBS'), ('GO_0007049', 'cell cycle', 112, 'cycle'), ('CHEBI_25212', 'metabolite', 118, 'metabolites'), ('NCBITaxon_10088', 'Mus <genus>', 299, 'mice'), ('GO_0007631', 'feeding behavior', 304, 'fed'), ('GO_0007565', 'female pregnancy', 340, 'postnatally'), ('GO_0034663', 'endoplasmic reticulum chaperone complex', 383, 'ETC complex I'), ('PR_000005800', 'carboxypeptidase A6', 387, 'complex I'), ('CHEBI_8756', 'RNA (poly(A))', 463, 'ROS')]
S163-PMC4934568	PMC4934568	10/2014	S163-PMC4934568	['note: enzymes and their alleles-mthfr: 5,10-methylanetetrahydrofolate reductase, comt: catechol-o-methyltransferase, mtr: methyltetrahydrofolate homocysteine methyl transferase, tcn2: transcobalamine ii, cbs: cystathionine β-synthase.']	N/A	N/A	[('SO_0001023', 'allele', 24, 'alleles'), ('CHEBI_20612', '5-methyltetrahydrofolate', 39, '5,10-methylanetetrahydrofolate'), ('CHEBI_18135', 'catechol', 87, 'catechol'), ('CHEBI_25345', 'methyltetrahydrofolate', 122, 'methyltetrahydrofolate'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 145, 'homocysteine'), ('PR_000016193', 'T-cell leukemia/lymphoma protein 1A', 184, 'transcobalamine II'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 204, 'CBS'), ('PR_000006022', 'lysosomal protective protein', 209, 'cystathionine β-synthase')]
S37-PMC5385335	PMC5385335	4/2017	S37-PMC5385335	['therefore, the aim of the present study was to investigate the reactivity to cck in the adult offspring of dams fed a control or a lp diet during lactation and gestation.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('QUESTION_ANSWERED_BY_THIS_WORK', 44)]	4	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 77, 'CCK'), ('UBERON_0007023', 'adult organism', 88, 'adult'), ('GO_0007631', 'feeding behavior', 112, 'fed'), ('GO_0007595', 'lactation', 146, 'lactation'), ('GO_0007565', 'female pregnancy', 160, 'gestation')]
S113-PMC5385335	PMC5385335	4/2017	S113-PMC5385335	['this result supports the hypothesis of an alteration in the postprandial feedback regulation of cck secretion and could be related to failure in short-term mechanisms of fi observed in lp rats (enhanced meal size and reduced satiety ratio).']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 82), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 123)]	5	[('GO_0065007', 'biological regulation', 82, 'regulation of ...'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 96, 'CCK'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 188, 'rats')]
S126-PMC5385335	PMC5385335	4/2017	S126-PMC5385335	['caption (fig): figure 3\n\n(a) basal and postprandial cholecystokinin (cck) secretion measured in plasma at different times before and after refeeding by elisa in control ( n \u2009=\u20099) and low-protein (lp) rats ( n \u2009=\u20099).']	N/A	N/A	[('PR_000006006', 'catenin alpha-1', 52, 'cholecystokinin'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 69, 'CCK'), ('UBERON_0001969', 'blood plasma', 96, 'plasma'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 200, 'rats')]
S148-PMC5385335	PMC5385335	4/2017	S148-PMC5385335	['vagal neurochemical phenotype and cck-1r signaling\nsince short-term regulation of fi by cck acts primarily via vagal nerve, the expression of cck-1r was measured in nodose ganglia.']	[('PROBABLE_UNDERSTANDING', 97)]	1	[('UBERON_0001456', 'face', 0, 'Vagal'), ('PR_000001202', 'C-C chemokine receptor type 6', 34, 'CCK-1R'), ('GO_0065007', 'biological regulation', 68, 'regulation'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 88, 'CCK'), ('UBERON_0001759', 'vagus nerve', 111, 'vagal nerve'), ('GO_0010467', 'gene expression', 128, 'expression'), ('PR_000001202', 'C-C chemokine receptor type 6', 142, 'CCK-1R'), ('UBERON_0001809', 'enteric ganglion', 165, 'nodose ganglia')]
S88-PMC6039335	PMC6039335	7/2018	S88-PMC6039335	['a molecular study revealed that early weaning and a high-starch diet activated precocious pre-adipocyte differentiation and fat accumulation by activating adipogenic peroxisome proliferator-activated receptor-gamma (pparg) and ccaat/enhancer-binding protein α pathways.']	[('INCOMPLETE_EVIDENCE', 18)]	1	[('CHEBI_28017', 'starch', 57, 'starch'), ('CL_0000136', 'fat cell', 94, 'adipocyte'), ('GO_0060612', 'adipose tissue development', 155, 'adipogenic'), ('GO_0005777', 'peroxisome', 166, 'peroxisome'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 216, 'PPARG'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 227, 'CCAAT/enhancer-binding protein α'), ('SO_0000165', 'enhancer', 233, 'enhancer')]
